0.66 USD
▼-0.06-8.25%
盘后 0.66 +0.76%
2026-11-20
市值
$7.84M
市盈率
—
EPS
-1.33
股息率
—
52 周区间
0.64 – 1.88
成交量
145.40K
Beta
0.92
目标价
—
52W 低 0.6452W 高 1.88
价格走势
公司简介
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name...